{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343469","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2026-08-11T12:00:14+00:00","discovered_at":"2026-08-11T12:05:00.311824+00:00","generated_at":"2026-08-11T12:06:00.293419+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prelude Therapeutics Q2 2026 net loss narrows to $13.9M; cash runway into Q2 2028","bullets":["Q2 2026 net loss $13.9M ($0.14/share) vs $31.2M ($0.41/share) in Q2 2025.","Cash, equivalents, restricted cash and marketable securities $155.2M at June 30, 2026; funds ops into Q2 2028.","R&D expense fell to $16.1M from $25.8M YoY; G&A to $5.0M from $6.4M.","Plan to initiate Phase 1 of PRT13722 (KAT6A degrader) in HR+ breast cancer in Q4 2026, pending IND.","Enrollment continues for PRT12396 JAK2V617F inhibitor; mCALR DAC program advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343469","json":"https://secwatch.observer/filing/0001193125-26-343469.json","markdown":"https://secwatch.observer/filing/0001193125-26-343469.md","text":"https://secwatch.observer/filing/0001193125-26-343469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/0001193125-26-343469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:06:00.293419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}